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Abstract
Background: Myostatin is a negative regulator of skeletal muscle growth. Truncating mutations in
the myostatin gene have been reported to result in gross muscle hypertrophy. Duchenne muscular
dystrophy (DMD), the most common lethal muscle wasting disease, is a result of an absence of
muscle dystrophin. Although this disorder causes a rather uniform pattern of muscle wasting,
afflicted patients display phenotypic variability. We hypothesized that genetic variation in myostatin
is a modifier of the DMD phenotype.
Methods: We analyzed 102 Japanese DMD patients for mutations in the myostatin gene.
Results: Two polymorphisms that are commonly observed in Western countries, p.55A>T and
p.153K>R, were not observed in these Japanese patients. An uncommon polymorphism of
p.164E>K was uncovered in four cases; each patient was found to be heterozygous for this
polymorphism, which had the highest frequency of the polymorphism observed in the Japanese
patients. Remarkably, two patients were found to be heterozygous for one of two novel missense
mutations (p.95D>H and p.156L>I). One DMD patient carrying a novel missense mutation of
p.95D>H was not phenotypically different from the non-carriers. The other DMD patient was
found to carry both a novel mutation (p.156L>I) and a known polymorphism (p.164E>K) in one
allele, although his phenotype was not significantly modified. Any nucleotide change creating a
target site for micro RNAs was not disclosed in the 3' untranslated region.
Conclusion: Our results indicate that heterozygous missense mutations including two novel
mutations did not produce an apparent increase in muscle strength in Japanese DMD cases, even
in a patient carrying two missense mutations.
Background
Duchenne muscular dystrophy (DMD), the most com-
mon inherited myopathy affecting approximately one in
3,500 males, is characterized by muscle dystrophin defi-
ciency. Dystrophin deficiency is caused by translational
reading frame shifts or nonsense mutations in the dys-
trophin gene [1]. DMD is a rapidly progressive disease
occurring during childhood that causes affected individu-
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als to lose their ability to walk by the age of 12 years old
before they succumb during their twenties due to either
respiratory or cardiac failure.
DMD is known to progress with a rather uniform pattern
of muscle weakness, However, the existence of a modify-
ing gene has been suggested due to the identification of
unusually mild DMD phenotypes [2-4]. Some phenotypic
variability has been explained by the precise locations of
the mutations and their effects on the dystrophin-dystro-
glycan complex [5,6] or by the identification of aberrant
splicing products from the dystrophin gene [7-10]. In
some cases, however, the same dystrophin mutation has
been reported to result in different phenotypes [11,12].
Although some phenotypic variability may arise due to
environmental factors, such as diet or exercise, there are
likely to be contributions from genetic components. In
fact, differences in genetic backgrounds have been shown
to influence the phenotypes of mice with a dystrophin-
glycoprotein complex disorder caused by a mutation in
the σ-sarcoglycan gene [13]. Therefore, it is highly plausi-
ble that unknown genetic factors modify the phenotype of
DMD.
Myostatin, also known as growth and differentiation fac-
tor 8 (GDF8), is a muscle-specific secreted peptide that
functions to limit muscle growth [14]. Several studies ana-
lyzing mutations of the myostatin gene have been con-
ducted in the Western worlds [15-17]. To date, six
polymorphisms and one intronic mutation have been
identified in the myostatin gene. One of the identified
polymorphisms (p.153K>R) has been associated with a
hypertrophic response in muscles due to strength training
[18]. Recently, an infant was identified with the first
homozygous disruption of the myostatin gene, which
resulted in the child being exceptionally muscular at birth
and unusually strong with increased muscle mass at four
years of age [19]. Remarkably, a single nucleotide change
creating a potential illegitimate micro RNA target site in
the 3' untranslated region of the sheep myostatin gene
was disclosed to cause translation inhibition leading to
the increase of muscularity [20].
Furthermore, disruption of endogenous myostatin by
gene or RNA targetings was shown to result in anatomic,
biochemical, and physiologic improvements in the dys-
trophic phenotype of mdx mice, a mouse model of DMD
with a nonsense mutation in the dystrophin gene [21,22],
including particularly prominent enlarged fiber diameters
and greatly reduced fatty fibrosis. These results suggest
that blocking endogenous myostatin is a potential strat-
egy for treatment of DMD [23].
We hypothesized that genetic variation in the myostatin
gene modifies the phenotype of DMD. Therefore, nucle-
otide changes in the myostatin gene were investigated in
Japanese DMD patients, resulting in the identification of
novel mutations.
Methods
Subjects
One hundred two DMD patients that were followed up at
Kobe University Hospital were enrolled into this study.
All of the mutations in the dystrophin genes were revealed
to introduce premature stop codons in the dystrophin
mRNA; 51 cases with mutations that induced a transla-
tional reading frame shift due to exon deletion or duplica-
tion, 31 cases with nonsense mutations, 12 cases with
mutations of one or a few nucleotides deletion or inser-
tion, and 8 cases with intron mutations that induced splic-
ing error (data not shown). The subjects' ages ranged from
1 to 31 years old (average: 10 years old). Regular clinical
check-ups, including determination of the serum creatine
kinase (CK) levels, were performed at the outpatient
clinic. The maximal voluntary isometric torque (MVIT)
produced by the elbow flexor muscles and the knee exten-
sor muscles was measured with a manual dynamometer
(Microfet2 digital muscle tester, Value Medical Supplies,
Hesperia, CA) with a precision of 0.1 Nm. A clear differ-
ence in the phenotypes was observed in the ages at which
the patients became wheelchair bound, which occurred
between the ages of 5 and 11 years old. Some patients,
however, were able to walk independently after they were
12 years old even though they carried mutations that
caused truncations of the dystrophin protein.
Protocols of this study were approved by the ethics com-
mittee of the Kobe University School of Medicine. Blood
samples were taken after written informed consent was
obtained.
Sequencing analysis of the myostatin gene
Genomic DNA samples were prepared from the periph-
eral blood of the patients via the standard phenol-chloro-
form extraction method and were used as templates for
PCR amplification. All three of the myostatin exons were
examined by PCR amplification and direct sequencing
(Fig. 1). Exons 1 and 3 of the myostatin gene were PCR
amplified as previously described [19]. Exon 1 was ampli-
fied as a 542-bp fragment, including 131 and 373 bp of
the 5' untranslated and protein coding regions, respec-
tively, as well as 38 bp of intron 1 (Fig. 1). Exon 3 was
amplified as a 536-bp fragment including 43 bp of intron
2 and 381 and 112 bp of the protein coding and 3'
untranslated regions, respectively (Fig. 1). Additionally a
middle part of the 3' untranslated region was amplified as
396-bp fragment using a set of two primers (3UF: 5'-CAT-
GTCATGCATCACAGAAAAGCAACTACT-3' and 3UR: 5'-BMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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CAAAATCCCAATTTACAAAACAGAA-3'), since a single
nucleotide change in this region of the sheep myostatin
gene has been shown to create a microRNA target site,
thereby leading translation inhibition [20]. Exon 2 was
amplified using two primers (2F: 5'-ATTAATATGGAG-
GGGTTTTGTTAATGG-3', 2R: 5'-GCTTAGGGAATTTG-
TAGCTATTTTCCA-3') that resulted in a 537-bp fragment,
including the 374 bp of exon 2, and 68 and 95 bp of
introns 1 and 2, respectively.
Denaturation of the DNA was performed at 96°C for 5
min, followed by 35 cycles of denaturation at 96°C for 1
min, annealing at 60°C for 1 min, and elongation at 72°C
for 1.5 min. The amplified products were analyzed on a
2% agarose gel and visualized by ethidium bromide stain-
ing. The PCR-amplified products were directly sequenced
using a BigDye Terminator v1.1 Cycle Sequencing kit
(Applied Biosystems, Foster City, CA) and an automated
DNA sequencer (ABI Prism 310 Genetic Analyzer; Perkin
Elmer Applied Biosystems). For subcloning sequencing,
the PCR-amplified products were cloned into the pT7 blue
T vector (Novagen, Madison, WI) and sequenced.
Sequencing results were compared with the wild-type
sequence (Genbank: AC073120).
Results
All three coding regions and a part of the 3' untranslated
region of the myostatin gene were successfully PCR ampli-
fied from genomic DNA; 102 DNA samples were sub-
jected to direct sequencing. Sequencing results of the exon
Myostatin and the human myostatin gene Figure 1
Myostatin and the human myostatin gene. The structure of myostatin, including the signal sequence (SS), and the regions 
of the propeptide and mature protein, is schematically described (Top). The numbers above the boxes indicate the amino-acid 
residue position. The vertical arrows indicate the locations of the two novel missense mutations and two nucleotides deletion 
identified in this study. The structure of the myostatin gene and the analyzed regions are schematically described (Bottom). 
Three coding regions (Exons 1, 2 and 3) and a part of the 3' untranslated region (3'UTR) of the myostatin gene were PCR 
amplified (boxes). The shaded and open boxes indicate the coding region and the sequenced region in the 3' untranslated 
region, respectively. Bold and thin horizontal lines indicate exons and introns, respectively. Horizontal arrows indicate the 
locations and directions of the primers used to amplify the regions. Numbers above the boxes indicate the nucleotide position 
according to the cDNA reference sequence in GenBank (accession no.: NM_005259), in which the "A" in the start codon is 
nucleotide #1. Numbers in the bottom indicate the size of each segment.
Exon 1 
1 373
Exon 2  Exon 3 
1128
373bp 381bp 374bp 131bp 38bp 95bp 68bp 112bp 43bp
747
SS Propeptide region Mature region
12 4 375 264 25 265
396bp
374 748 2185 2580
p. 95 D>H p.156 L>I c.2264-2265 del AT
3’UTRBMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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1-encompassing region disclosed completely normal
sequences in all of the samples except for one nucleotide
change in one sample. In this case (case 712), direct
sequencing revealed overlapping G and C peaks at the
283rd position of the myostatin cDNA (c.283G>G/C) (Fig.
2). Because this nucleotide position is a G in the wild-type
sequence, the presence of a C at this position was deter-
mined to be a mutation (c.283G>C).
c.283G>C changed the codon corresponding to the 95th
amino-acid residue of myostatin from GAT to CAT, which
substituted an Asp residue to a His residue (p.95D>H).
This missense mutation was located at a conserved
amino-acid residue in the propeptide region (Fig. 1) [24]
and was predicted to affect the function of myostatin.
Clinical examination of muscle strength, however, failed
to reveal a clear difference between the DMD patient car-
rying this nucleotide change and the other DMD patients.
At 8 years old, the patient could not stand up by himself,
but was able to walk independently with a waddling gait.
In the exon 2-encompassing region, overlapping G and A
peaks at the 490th nucleotide of the myostatin cDNA
(c.490G>G/A) were uncovered in four samples. c.490G>A
corresponded to a known polymorphism that changes a
GAG codon for Glu to a AAG codon for Lys at the position
A novel mutation in exon 1 of the myostatin gene Figure 2
A novel mutation in exon 1 of the myostatin gene. A part of the sequencing results for exon 1 of the myostatin gene 
from a DMD patient (case 712) is shown (patient). Overlapping G and C peaks are present at the 283rd nucleotide of the 
myostatin cDNA (c.283G>G/C) (Top). The single nucleotide change from G to C at the 283rd nucleotide of the myostatin 
cDNA (c.283G>C) changed a GAT codon to a CAT codon at the position corresponding to the 95th amino-acid residue of 
myostatin (p.95D>H)(boxes). The wild type sequence is shown below (control).
(p. 95 D) c.283 G 
(p. 95 D>D/H) c.283 G>G/C 
control
patientBMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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corresponding the 164th amino-acid residue of myostatin
(p.164E>K) [15]. The allele frequency of c.490G>A was
2.0% (4 of 204 alleles). Interestingly, in one of the four
samples with c.490G>A (case 549), overlapping C and A
peaks were also found at the 466th nucleotide of the
myostatin cDNA (c.466C>C/A) (Fig. 3). Subsequent sub-
cloning sequencing disclosed the presence of two clones;
one was identical to the wild-type sequence (Fig. 3),
whereas the second clone carried the two nucleotide
changes observed with direct sequencing: c.466C>A and
c.490G>A (Fig. 3). c.466C>A, which has not been previ-
ously described, changed a CTA codon for Leu to a ATA
codon for Ile (p.156L>I). Because the novel missense
mutation was located at a conserved residue, this muta-
tion was predicted to disrupt myostatin function (Fig. 1),
particularly when it was combined with the second amino
acid substitution located only eight amino-acid residues
away. Clinical examination of the patient carrying the
allele encoding two nucleotide changes did not disclose a
clear mild DMD phenotype in the 14 year old. He was
wheel-chair bound at 7 years old. The phenotypes of the
other three DMD cases carrying c.490G>A in one allele
were clinically indistinguishable from the other DMD
patients.
None of these Japanese DMD cases carried p.55A>T or
p.153K>R, frequently observed polymorphisms in the
United States, or the single nucleotide change in intron 2
that has been reported to result in gross muscular hyper-
trophy (Table 1) [15]. Moreover, examination of the exon
3-encompassing region (Fig. 1) did not disclose any
nucleotide changes in the genomic samples. This was
compatible with results obtained in previous studies.
Sequencing of the 396-bp fragment of the 3' untranslated
region revealed no nucleotide change, especially in the
stretch of ACGTTCCA (an underlined G is 2402nd nucle-
otide where the substitution of G with A has been
reported to create the octamer motif for the micro RNA
target site in the sheep myostatin gene [20]). Exception-
ally, one DMD case (case 100) was found to have a dele-
tion of AT dinucleotides at 2264 and 2265th position
(c.2264-2265delAT)(Fig. 4). Though the possibility for
the deletion to create the motif for the microRNA target
site was searched in this deletion sequence, no candidate
motif for the microRNA target site was pointed out [25].
Therefore this deletion seemed a polymorphism in the 3'
untranslated region.
Discussion
Myostatin is a negative regulator of muscle growth that is
attracting attention as a novel target for increasing muscle
growth in cases of DMD [23]. In this study, we conducted
extensive sequence analysis of the myostatin genes in 102
Japanese DMD patients. As a result, two novel missense
mutations (p.95D>H and p.156L>I) were identified (Figs.
2 and 3). In addition, a known polymorphism
(p.164E>K) was identified in four of the DMD patients.
Because one of the DMD patients carried p.156L>I and
p.164E>K in the identical allele (Fig. 3), the overall
mutant allele frequency was 2.5% (5 of 204 alleles). No
truncation mutations in the myostatin gene, however,
were identified in our study. In particular, the intron
mutation that introduces a premature stop codon in
myostatin mRNA resulting in marked muscle hypertrophy
[19,26] was not observed. Although a single nucleotide
change in the 3' untranslated region of the sheep myosta-
tin gene was shown to lead translational inhibition [20],
any nucleotide change creating the octamer motif for the
micro RNA target site was not disclosed in DMD patients.
Exceptionally, one case was disclosed to harbor two nucle-
otides deletion in the 3' untranslated region (c.2264-
2265delAT) in one myostatin gene (Fig. 4). It needs fur-
ther study to clarify the meaning of this deletion.
Both of the novel mutations (p.95D>H and p.156L>I)
were predicted to be pathogenic because they are located
at conserved amino-acid residues at the propeptide region
of myostatin [24]. The phenotypes of the DMD cases het-
erozygous for p.95D>H, p.164E>K, or p156L>1 and
p164E>K, however, were not significantly different from
the phenotypes of the other DMD cases. It has been
reported that a mother carrying a truncation mutation in
intron 2 of the myostatin gene appeared muscular,
whereas her son, who was homozygous for the same
mutation, showed remarkable muscle hypertrophy [19].
Therefore, the muscle volume and strength of individuals
that are heterozygous for myostatin mutations may not be
markedly affected by these mutations. Considering that
women with one missense polymorphism in the propep-
tide region of myostatin exhibited increase in muscle vol-
ume in response to strength training [18], it is supposed
that the case with two amino acid substitutions can be
phenotypically modified by providing proper muscle
rehabilitation. Future studies will address this supposi-
tion.
In order to clarify the roles of the two novel mutations, it
may be necessary to identify cases in which the mutations
are homozygous. In previous studies, homozygous poly-
morphisms in the myostatin gene have been reported to
cause no clear changes in muscle volume or strength
[15,16,27]. In this study, some of the DMD patients had
mild phenotypes, such as an ability to walk independ-
ently past the age 12 years old (data not shown). Although
we hypothesized that in these cases the mild phenotypes
were a result of a modifier of the DMD phenotype, these
patients did not have mutations in their myostatin genes.
Particularly we have reported that aberrant splicing prod-
ucts of the dystrophin gene are a modifier of DMD [8,10].BMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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The variability of the human myostatin gene has been
studied in Western countries (Table 1) [15-17,27]. To
date, six nucleotide changes (two are common and four
are uncommon) have been identified in the myostatin
Table 1: Polymorphisms in the myostatin gene
mutation Japan USA Caucasian USA African American Italy Belgium
(n = 102) (n = 167*) (n = 95**) (n = 96*) (n = 93**) (n = 450*) (n = 120**) (n = 57)
p.55A>T 0 12 (het) 19 (het) 2(hom) 2 (het) 0
p.153K>R 0 7 (het) 24 (het) 3 (hom) 6 (het) 1 (hom) 1
n number of individuals studied (* p.55A>T, **p.153K>R)
Data are from the USA, Italy, and Belgium [15-17, 27].
A novel mutation in exon 2 of the myostatin gene Figure 3
A novel mutation in exon 2 of the myostatin gene. A part of the sequencing results for exon 2 of the myostatin gene of 
one DMD case (case 549) is shown. Overlapping peaks were observed at two locations corresponding to c.466C>C/A and 
c.490G>G/A in one DNA sample (Top). Subcloning sequencing disclosed two different sequences: one had a completely nor-
mal sequence (Bottom 2), whereas the other one had two nucleotide changes (Bottom 1). The G to A change at the 490th 
nucleotide of the myostatin cDNA (c. 490G>A) matched with the previously described p.164E>K mutation (box). The other 
nucleotide change from C to A at the 466th nucleotide of the myostatin cDNA (c.466C>A) changes a CTA codon for Lys to a 
ATA codon for Ile at the position corresponding to the 156th amino-acid residue of myostatin (p.156L>I) (box).
c.466 C>C/A
(p.156 L>L/I )
c.490 G>G/A
(p.164 E>E/K)
c.466 C 
(p.156 L)
c.490 G 
(p.164 E)
c.466 C>A
(p.156 L>I )
c.490 G>A 
(p.164 E>K)
subcloning sequencing
2
1BMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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gene (Table 1 and 2). Two polymorphisms, a G to A
change at codon 55 in exon 1 (p.55A>T) and an A to G
substitution in exon 2 (p.153K>R), were represented in
6.6% and 9.8% of the examined alleles in the USA [15]. In
an Italian study [16], the p.55A>T and p.153K>R were
identified in 0.2% and 3.3% of the examined alleles,
respectively. In a study in Belgium, only one individual
from 57 males was found to be heterozygous for
p.153K>R [17]. None of the Japanese patients in this
study, however, carried p.55A>T or p.153K>R (Table 1).
These differences in the incidences of the polymorphisms
Table 2: Rare mutations in the myostatin gene in the Western world and Japan
mutation Japan (n = 102) USA (n = 189) Italy (n = 120) Belgium (n = 57)
p.95D>H 1 ND ND ND
p.156L>I 1 ND ND ND
p . 1 6 4 E > K 4200
p.185R>T 0 ND 1 ND
p . 1 9 8 P > A 0100
p.225I>T 0 2 0 ND
c.747+8G>A 0 1 0 ND
c.2264-2265 del AT 1 ND ND ND
ND not determined, n number of individuals studied
All numbers show individuals with mutation in heterozygote
Data are from the USA, Italy, and Belgium [15-17, 27].
A novel deletion mutation in the 3' untranslated region of the myostatin gene Figure 4
A novel deletion mutation in the 3' untranslated region of the myostatin gene. A part of the sequencing result for 
the 3' untranslated region of the myostatin gene is shown. In the control all of the sequences matched with that of the wild-
type sequence (Genbank: AC073120), including the repeat of AT dinucleotides (boxes) (control). In the sequence of one DMD 
case (case 100) the repeat of AT dinucleotides was not present, removing AT dinucleotides at 2264 and 2265th nucleotide 
(c.2264-2265delAT) (patient).
control
patient
c.2264-2265delATBMC Medical Genetics 2007, 8:19 http://www.biomedcentral.com/1471-2350/8/19
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demonstrate that there is a racial difference in the spectra
of these polymorphisms.
It is remarkable that four of the 102 patients were hetero-
zygous for p164E>K, which corresponds an allele fre-
quency of 2.0% in the Japanese patients (Table 1). The
p164E>K allele was identified in only 2 out of 189 indi-
viduals in the USA, and was not observed in 120 Italians
and 57 Belgians [15-17]. In one of the Japanese DMD
patients carrying p.164E>K, a second p.156L>I mutation
was found in the same allele (Fig. 3). Considering that
p.164E>K was identified in both the Americans and Japa-
nese populations, p.164E>K may be an old polymor-
phism that originated in a common ancestor of the two
populations or the polymorphism is located at hot spot
for nucleotide changes.
Conclusion
The present study, although limited to DMD cases,
showed the rare occurrence of mutations in the myostatin
gene in Japanese subjects. Our results indicate that heter-
ozygous missense polymorphisms including two novel
mutations did not produce an apparent increase in muscle
volume or strength in Japanese DMD cases, even in a
patient carrying two amino acid substitutions.
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